GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ViroPharma, Inc. (FRA:VPH) » Definitions » Price-to-Owner-Earnings

ViroPharma, (FRA:VPH) Price-to-Owner-Earnings : (As of Jun. 22, 2024)


View and export this data going back to . Start your Free Trial

What is ViroPharma, Price-to-Owner-Earnings?

As of today (2024-06-22), ViroPharma,'s share price is €36.08. ViroPharma, does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for ViroPharma,'s Price-to-Owner-Earnings or its related term are showing as below:


FRA:VPH's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.85
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-22), ViroPharma,'s share price is €36.08. ViroPharma,'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2013 was €-0.77. Therefore, ViroPharma,'s PE Ratio for today is At Loss.

As of today (2024-06-22), ViroPharma,'s share price is €36.08. ViroPharma,'s EPS without NRI for the trailing twelve months (TTM) ended in was €-0.77. Therefore, ViroPharma,'s PE Ratio without NRI for today is At Loss.


ViroPharma, Price-to-Owner-Earnings Historical Data

The historical data trend for ViroPharma,'s Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroPharma, Price-to-Owner-Earnings Chart

ViroPharma, Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ViroPharma, Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ViroPharma,'s Price-to-Owner-Earnings

For the Biotechnology subindustry, ViroPharma,'s Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroPharma,'s Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ViroPharma,'s Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ViroPharma,'s Price-to-Owner-Earnings falls into.



ViroPharma, Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ViroPharma,'s Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=36.08/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViroPharma,  (FRA:VPH) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


ViroPharma, Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of ViroPharma,'s Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroPharma, (FRA:VPH) Business Description

Traded in Other Exchanges
N/A
Address
ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. It is a biotechnology company which develops and commercializes products that address serious diseases, used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On 8 January 2010, the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is consists of programs such as C1 esterase inhibitor [human], maribavir for cytomegalovirus infection, VP20621: prevention of recurrent CDAD and VP20629: treatment of Friedreich's Ataxia. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.

ViroPharma, (FRA:VPH) Headlines

No Headlines